PB1879: EFFICACY AND SAFETY OF CPX-351 COMPARED TO STANDARD OF CARE CHEMOTHERAPY IN A REAL-LIFE SETTING: SUPPORTING PREVIOUS EVIDENCE AND FACING NEW CHALLENGES

Hemasphere · 2023 · PMC10429887

Europe PMC

hedged sentence

0.6000

closest p · 12.0× alpha

0.6000

boldest claim

The sentences

showed a trendp = 0.6not close (p > 0.1)

Results: With a median follow up of 21.2 months, CPX-351 showed a trend towards better OS (not reached vs 15.4 months, p = 0.6) and lower disease-related mortality (25.0% vs 83.3%), compared to SOC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.